Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Capital Expenditures: 2020-2024

Historic Capital Expenditures for InMed Pharmaceuticals (INM) over the last 5 years, with Jun 2024 value amounting to $9,293.

  • InMed Pharmaceuticals' Capital Expenditures was N/A to $2 in Q1 2024 from the same period last year, while for Mar 2024 it was -$179,074, marking a year-over-year change of. This contributed to the annual value of $9,293 for FY2024, which is 94.19% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Capital Expenditures stood at $9,293 for FY2024, which was down 94.19% from $160,014 recorded in FY2023.
  • InMed Pharmaceuticals' Capital Expenditures' 5-year high stood at $160,014 during FY2023, with a 5-year trough of $1,725 in FY2021.
  • Its 3-year average for Capital Expenditures is $69,472, with a median of $39,108 in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 95.95% in 2021, then spiked by 2,167.13% in 2022.
  • InMed Pharmaceuticals' Capital Expenditures (Yearly) stood at $42,573 in 2020, then slumped by 95.95% to $1,725 in 2021, then surged by 2,167.13% to $39,108 in 2022, then surged by 309.16% to $160,014 in 2023, then crashed by 94.19% to $9,293 in 2024.